Related Articles
Precision medicine for respiratory diseases: A current viewpoint
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Targeted therapy in HER2‑positive breast cancer (Review)